Notably, in both NSCLC and Melanoma, there is an increase in the proportion of CXCL13+ T cells in the TME following anti-PD-1-treatment, which lack markers of terminal exhaustion displaying a phenotype of T-exhausted precursor cells (Texp) (21). The gene discussed is CXCL13; the disease is non-small cell lung carcinoma.